The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

Overview

The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy.

Detailed description

This is a prospective multi-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinoma tumors in patients who are diagnosed with unresectable locally advanced (Stage 3) or oligometastatic disease (Stage 4).

The type of design is exploratory and is considered interventional. Following histotripsy, subjects will undergo imaging ≤36-hours post-index procedure. Additionally, subjects will be followed at 7-day, 14-day, 30-day, 60-day, 120-day, and 180-day timepoints.

Interventions

• Device HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
  Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.

Primary outcome measures

• Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy [Time frame: 30 days post histotripsy procedure]

Eligibility criteria

Inclusion criteria

• Subject is ≥18 years of age.
• Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
• Subject is diagnosed with unresectable pancreatic adenocarcinoma (locally advanced \[Stage 3\] or oligometastatic disease \[Stage 4\]) confirmed via CT or MR imaging ≤14 days prior to the planned index procedure.

NOTE: If Stage 4 disease, there must be ≤5 metastatic tumors, the tumors must be located only in the liver and/or lung, and the metastatic tumors must be stable.

• Subject is not a surgical candidate and has received chemotherapy ≥8 weeks.
• Subject can tolerate general anesthesia.
• Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline.
• Subject meets the following criteria ≤14 days prior to the planned index procedure date:

• Hemoglobin ≥ 9 g/dL,
• Neutrophil count >1.0 x 10\^9/L,
• Platelet >50 x 10\^9/L,
• Total bilirubin ≤2.5x Institutional Upper Limit of Normal (IULN),
• Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5x IULN,
• International Normalized Ratio (INR) value <1.5,
• Serum creatinine <2.0mg/dL or an estimated glomerular filtration rate (eGFR) ≥45mL/min.
• The targeted pancreatic tumor is ≥2 cm in longest diameter.
• The planned histotripsy treatment volume is ≥1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging.
• Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.
• Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas.

Exclusion criteria

• Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
• Subject has had prior pancreatic, bilioenteric, or gastric surgery.
• Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
• Subject has an uncorrectable coagulopathy.
• Subject has a life expectancy of less than six (6) months.
• Subject has a biliary or pancreatic stent and/or percutaneous biliary tube that encompasses the planned histotripsy treatment volume.
• Subject has metastases to organs other than the liver and/or lung (e.g., bone, brain, peritoneum).
• Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
• Subject has an active duodenal or gastric ulcer requiring medical management.
• Subject is undergoing active chemotherapy for any cancer ≤7 days prior to planned index procedure date.\*
• Subject is undergoing active immunotherapy or targeted therapies ≤30 days prior to planned index procedure date.
• Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation).
• Subject has a planned cancer treatment (e.g., pancreatic surgery, targeted therapy, immunotherapy) exclusive of chemotherapy, ≤30 days post index procedure.
• Subject has planned chemotherapy ≤14 days post index procedure.\*
• Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency).
• In the investigator's opinion, histotripsy is not a treatment option for the subject.
• Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
• Subject's tumor is not treatable by the System's working ranges (refer to User Guide).

(\*) Subject must not be off chemotherapy >21 days in total.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Spain · 1 center

• Hospital de la Santa Creu i Sant Pau — Barcelona

Identifiers

NCT: NCT06282809 · CSP3325

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗